Tesamorelin (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously, preferably in the evening to coincide with nocturnal GH release. The

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light.
5. Use within 7 days when reconstituted with bacteriostatic water. At 3.33 mg/mL, 1 unit = 0.01 mL » 33.3 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at 2 to 8 °C; newer formulations (Egrifta SV) stable at 20 to 25 °C before reconstitution.
• Reconstituted (with bacteriostatic water): refrigerate at 2 to 8 °C; use within 7 days.
• Reconstituted (with sterile water): use immediately; discard any unused portion.
• Do not freeze reconstituted solution; avoid repeated freeze-thaw cycles.

Supplies Needed

Plan based on an 8 to 16 week daily protocol at the standard 2 mg dose.

Peptide Vials (Tesamorelin, 10 mg each):

• 8 weeks: ~11 vials (105 mg total).
• 12 weeks: ~17 vials (161 mg total).
• 16 weeks: ~22 vials (217 mg total).

Insulin Syringes (U-100, 1 mL capacity):

• Per week: 7 syringes (1/day).
• 8 weeks: 56. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (11 vials): 4 bottles. 12 weeks (17 vials): 6 bottles. 16 weeks (22 vials): 7 bottles.

Alcohol Swabs:

• Per week: 14 swabs. 16 weeks: 224 swabs (3 x 100-count boxes).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container.
• Rotate injection sites (abdomen at least 2 inches from navel, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Monitor IGF-1 levels periodically due to potent GH stimulation; observe blood glucose in diabetic

patients.

• Document daily dose and site rotation to maintain consistency.

How This Works

Tesamorelin mimics natural human GHRH by binding to pituitary GHRH receptors, triggering pulsatile growth hormone secretion and consequent IGF-1 elevation. This cascade promotes lipolysis (fat breakdown), protein synthesis, and favorable metabolic shifts. In HIV-associated lipodystrophy, daily tesamorelin significantly reduces visceral adipose tissue and improves lipid profiles over 6 to 12 months. Research also explores tesamorelin's potential to reduce liver fat in NAFLD patients and enhance cognitive function in older adults by restoring age-related GH/IGF-1 declines.

Benefits & Side Effects

Observations from clinical trials and FDA-approved use.

• Significant reduction in visceral adipose tissue: measurable after 3 to 6 months.
• Improved lipid profiles: and potential liver fat reduction in NAFLD.
• Enhanced cognitive function: in older adults (research ongoing).
• Well-tolerated with maintained benefits during continuous use up to 52 weeks.
• Injection-site reactions: mild redness, itching, pain, or bruising at injection area.
• Musculoskeletal symptoms: joint pain, muscle aches, peripheral edema (mild swelling).
• Carpal tunnel symptoms: occasional tingling or numbness in extremities (dose-dependent, reversible).
• Metabolic monitoring: IGF-1 elevation requires monitoring; small increases in HbA1c observed in some

patients.

• Contraindications: active malignancies, pregnancy, known hypersensitivity to tesamorelin or mannitol.

Lifestyle Factors

Complementary strategies for best outcomes.

• Combine with a balanced, protein-forward diet to support GH/IGF-1 anabolic effects.
• Integrate resistance training and aerobic activity to maximize fat loss and metabolic benefits.
• Prioritize 7 to 9 hours of quality sleep to optimize natural GH pulsatility.
• Manage stress through mindfulness or relaxation techniques to support adherence and recovery.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol swabs; allow to air-dry completely.
2. Pinch a skinfold at the injection site (abdomen preferred, at least 2 inches from navel).
3. Insert the needle at 90 degrees (if adequate subcutaneous fat) or 45 degrees (if lean).
4. Release the pinch, then inject slowly; wait 2 to 3 seconds before withdrawing.
5. Rotate injection sites systematically (left/right abdomen, thighs, upper arms) to prevent lipohypertrophy.
6. Dispose of used syringes immediately in a puncture-proof sharps container.

References

Source citations for further reading.

1. Tesamorelin (LiverTox: NIDDK, 2018).
2. Falutz J et al. Effects of tesamorelin in HIV-infected patients with excess abdominal fat (J Clin Endocrinol Metab, 2010).
3. Safety and metabolic effects of tesamorelin in patients with type 2 diabetes (PLoS ONE, 2017).
4. EGRIFTA SV (tesamorelin) Full Prescribing Information (Theratechnologies, FDA Label, 2024).